BCL201 + idelalisib

- **BCL201 + idelalisib** is an experimental combination therapy used in hematological malignancies, notably follicular lymphoma (FL) and mantle cell lymphoma (MCL). BCL201 is an investigational agent; idelalisib (brand name: Zydelig) is a selective PI3K delta inhibitor approved for certain lymphomas. The combination was studied to assess safety, tolerability, and dose-limiting toxicities in Phase Ib trials. The rationale is based on idelalisib’s ability to alter cell survival signaling (PI3Kδ inhibition), sensitizing malignant B cells to cytotoxic agents, while BCL201’s target and mechanism are not fully disclosed but may involve Bcl-2 family proteins or related apoptosis pathways[3][4][7]. - Mechanistically, idelalisib blocks PI3Kδ in B cell receptor signaling, leading to reduced survival, migration, and proliferation of malignant B cells. BCL201 is presumed to act synergistically by enhancing apoptosis, possibly via BCL2 inhibition or modulation, though exact molecular targets for BCL201 are not comprehensively disclosed in available sources[3][4][7].

Brand names

Zydelig

Other names

BCL201BCL-201BCL 201Zydeligidelalisib